title: Ulcerative colitis and Crohn's disease.
abstract: As new drugs emerge from the pipeline for the nearly 2 billion patients globally diagnosed with ulcerative colitis and Crohn's disease, sales of therapies for these conditions are expected to increase from $7.35 billion today to $11.05 billion in 2022.
authors.forename: Kunj
authors.initials: K
authors.lastname: Gohil
authors.forename: Brielle
authors.initials: B
authors.lastname: Carramusa